FAF
VRTX icon

Första AP-fonden’s Vertex Pharmaceuticals VRTX Stock Holding History

Första AP-fonden’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-53,480
Closed -$24.2M – 505
2025
Q4 		$24.2M Sell
53,480
-1,520
-3% -$655K 0.14% 125
2025
Q3 		$21.5M Buy
55,000
+3,000
+6% +$1.25M 0.13% 145
2025
Q2 		$23.2M Sell
52,000
-6,200
-11% -$2.86M 0.15% 125
2025
Q1 		$28.2M Sell
58,200
-500
-0.9% -$233K 0.21% 86
2024
Q4 		$23.6M Sell
58,700
-1,200
-2% -$556K 0.17% 99
2024
Q3 		$27.9M Buy
59,900
+6,000
+11% +$2.88M 0.21% 85
2024
Q2 		$25.3M Sell
53,900
-1,800
-3% -$781K 0.22% 83
2024
Q1 		$23.3M Sell
55,700
-18,000
-24% -$7.61M 0.2% 100
2023
Q4 		$30M Buy
73,700
+600
+0.8% +$222K 0.3% 62
2023
Q3 		$25.4M Buy
73,100
+1,000
+1% +$350K 0.28% 65
2023
Q2 		$25.4M Buy
72,100
+2,400
+3% +$809K 0.27% 69
2023
Q1 		$22M Buy
69,700
+8,300
+14% +$2.49M 0.26% 79
2022
Q4 		$17.7M Buy
61,400
+6,600
+12% +$2.01M 0.2% 108
2022
Q3 		$15.9M Buy
54,800
+900
+2% +$259K 0.19% 110
2022
Q2 		$15.2M Sell
53,900
-3,600
-6% -$964K 0.2% 111
2022
Q1 		$15M Sell
57,500
-19,800
-26% -$4.7M 0.17% 117
2021
Q4 		$17M Buy
77,300
+1,100
+1% +$214K 0.17% 120
2021
Q3 		$13.8M Sell
76,200
-2,100
-3% -$410K 0.16% 138
2021
Q2 		$15.8M Buy
78,300
+18,300
+31% +$3.83M 0.19% 113
2021
Q1 		$12.9M Sell
60,000
-11,300
-16% -$2.48M 0.18% 126
2020
Q4 		$16.9M Buy
71,300
+12,900
+22% +$2.96M 0.25% 73
2020
Q3 		$15.9M Buy
58,400
+23,100
+65% +$6.37M 0.33% 60
2020
Q2 		$10.2M Buy
35,300
+4,000
+13% +$1.08M 0.27% 84
2020
Q1 		$7.45M Buy
+31,300
New +$7.18M 0.27% 95

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Första AP-fonden's VRTX Position: Q1 2026 in Review

Första AP-fonden sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 53,480 shares — an estimated $24.2M sold.

Första AP-fonden first reported a position in VRTX in Q1 2020 and held it in 24 quarters. The position peaked at $30M in Q4 2023. 1,699 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Första AP-fonden reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Första AP-fonden sold 53,480 Vertex Pharmaceuticals shares in Q1 2026, an estimated $24.2M.
  • Första AP-fonden first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 24 quarters.
  • Första AP-fonden's Vertex Pharmaceuticals position peaked at $30M in Q4 2023.
  • 1,699 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Första AP-fonden's 13F filing for Q1 2026.